"Based on the results from the total study samples, including samples as early as 8 weeks of pregnancy, the Sequenom SEQureDx RNA-based technology demonstrated a 100% positive predictive value (PPV) and a 99.9% negative predictive value (NPV). The SEQureDx technology achieved a better than 99% detection rate, with less than a 1% false positive rate."
-- Reuters
This is just a short follow up to my previous post, "Promising Discoveries and Tweaked Results." Upon further investigation of Sequenom, a Reuters report was released in January in response to test results released by Sequenom on SEQureDx (shown above). Food for thought: clinical trials using free fetal DNA as an aneuploidy detection method released just a year prior to those of Sequenom posted a modest, yet very respectable true positive detection rate of 66.7% and false positive rate at only 1.8%. Even these results exceeded those of current detection methods. Considering the overly prodigious results posted by Sequenom on January 28th, it's really no surprise that even the most informed investors bought into the Sequenom hype. I believe it's really up for grabs now. The technology behind SEQureDx is sound--I really believe that. From analysis of the data, I do not believe that true positive and false negative percentages should be in the range of that reported in January, but if accurate results had been printed, I really think that they would have shown a significant increase over traditional methods. If Sequenom can make it through the chaos of all of these class action lawsuits and maintain enough capital to continue with their current clinical trials, success is all but guaranteed. Currently trading at an ultra low after the decimating news on April 30th, SQNM just could be the ultimate steal. Take it with a grain of salt, but keep an eye on SQNM.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment